A Landscape Review of Oligonucleotide Therapy Development for Neurological Disorders
Time: 8:30 am
day: Day 1
Details:
- The drug landscape, displaying critical data-driven therapeutic and clinical trial highlights, as well as current trends
- A look at the developer landscape, allowing for understanding of the commercial market involving these drugs’ development
- The outlook for the future of oligonucleotide therapies for the CNS from a preclinical and clinical perspective
